Friday , March 29 2024
Home / SNB & CHF / Swiss pharma executive gets US sanction for insider trading  

Swiss pharma executive gets US sanction for insider trading  

Summary:
The culprit was a head of strategy at Roche, which is headquartered in Switzerland at the Roche tower in Basel. The US Securities and Exchange Commission (SEC) has fined Lorenz Erne, a former senior executive at Swiss pharmaceutical firm Roche, for insider trading and ordered him to pay back the ill-gotten profits. Erne accepted the accusations and agreed to the terms of a settlement with the SEC, according to an SEC documentexternal link published on Thursday. He has to pay back 9,228 (CHF156,000) plus a fine of ,614 within 14 days to the SEC “for transfer to the general fund of the United States Treasury”. The case concerns insider trading in the shares of American gene therapy company Spark Therapeutics ahead of a February 25, 2019, announcement that a

Topics:
Swissinfo considers the following as important: , , , , ,

This could be interesting, too:

Connor O'Keeffe writes Is the Violence in Haiti a Preview of a Libertarian Society?

Douglas French writes Tapping 401ks to Pay the Bills

Marc Chandler writes Dollar Extends Gains Against the Yen but Broadly Firmer Ahead of the FOMC

Grey Haneberg writes Reimagining Public Safety – The Case for Privatizing Security

Swiss pharma executive gets US sanction for insider trading  

The culprit was a head of strategy at Roche, which is headquartered in Switzerland at the Roche tower in Basel.

The US Securities and Exchange Commission (SEC) has fined Lorenz Erne, a former senior executive at Swiss pharmaceutical firm Roche, for insider trading and ordered him to pay back the ill-gotten profits.

Erne accepted the accusations and agreed to the terms of a settlement with the SEC, according to an SEC documentexternal link published on Thursday. He has to pay back $159,228 (CHF156,000) plus a fine of $79,614 within 14 days to the SEC “for transfer to the general fund of the United States Treasury”.

The case concerns insider trading in the shares of American gene therapy company Spark Therapeutics ahead of a February 25, 2019, announcement that a Roche affiliate company and Spark had reached a merger agreement.

Erne “traded while in possession of material, non-public information that he learned in the course of his employment at Hoffmann-La Roche”, making profits as Spark shares rose by 120%.

At the time of the trading, Erne was head of the Strategy Office at Roche Global Technical Operations in the Pharmaceuticals Division.


Tags: ,,,
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.

Leave a Reply

Your email address will not be published. Required fields are marked *